CompletedNot Applicable

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder

Pakistan80 participantsStarted 2025-05-06

Plain-language summary

The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Diagnosed with major depressive disorder (MDD) per DSM-5 criteria. Baseline depression score indicating moderate to severe depression Ability to provide informed consent Willing to comply with study requirements Exclusion Criteria: History of bipolar disorder, schizophrenia, or other psychotic disorders Current substance use disorder (within past 6 months) Active suicidal ideation requiring urgent intervention Pregnancy or breastfeeding Known hypersensitivity to study medications

What they're measuring

Change in Depression Severity (measured by HAMD-17)

Timeframe: 6 weeks

Trial details

NCT IDNCT06957223

SponsorAsad Ullah Jan

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-11-30

View on ClinicalTrials.gov More Major Depressive Disorder (MDD) trials